Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Romiplostim N01 in Promoting Platelet Reconstruction After Haploidentical Allogeneic Stem Cell Transplantation in Patients With Hematologic Malignancies

NCT07321626 is registered in ClinicalTrials.gov with First Affiliated Hospital of Zhejiang University as lead sponsor.

NCT NCT07321626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07321626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Romiplostim N01 in Promoting Platelet Reconstruction After Haploidentical Allogeneic Stem Cell Transplantation in Patients With Hematologic Malignancies
Lead sponsor
First Affiliated Hospital of Zhejiang University
Phase
Phase 1
Overall status
Recruiting
Start date
June 1, 2025
Completion date
December 31, 2027
Enrollment
130 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, delayed platelet engraftment, hsct, mds (myelodysplastic syndrome)